Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1991 3
1992 3
1993 3
1994 3
1995 3
1996 2
1997 5
1998 4
1999 3
2000 2
2001 2
2002 2
2003 3
2004 4
2005 8
2006 7
2007 4
2008 7
2009 7
2010 1
2011 8
2012 2
2013 4
2014 7
2015 6
2016 4
2017 3
2018 3
2019 4
2020 3
2021 3
2022 2
2023 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R, Wilt TJ. MacDonald R, et al. Urology. 2005 Oct;66(4):780-8. doi: 10.1016/j.urology.2005.05.001. Urology. 2005. PMID: 16230138
Eight trials were placebo-controlled studies, two were alfuzosin versus alternative alpha-blockers, and one was alfuzosin versus finasteride and combination alfuzosin/finasteride therapy. ...Alfuzosin increased the peak urinary flow more than did place …
Eight trials were placebo-controlled studies, two were alfuzosin versus alternative alpha-blockers, and one was alfuzosin vers …
Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.
Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP. Liu C, et al. PLoS One. 2015 Aug 5;10(8):e0134589. doi: 10.1371/journal.pone.0134589. eCollection 2015. PLoS One. 2015. PMID: 26244843 Free PMC article.
It is unclear whether alfuzosin has similar efficacy as Tamsulosin in the management of ureteral stones. OBJECTIVE: To perform a systematic review and analysis of literatures comparing Alfuzosin with Tamsulosin or standard conservative therapy for the treatment of u …
It is unclear whether alfuzosin has similar efficacy as Tamsulosin in the management of ureteral stones. OBJECTIVE: To perform a syst …
The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo.
Kwon JK, Cho KS, Oh CK, Kang DH, Lee H, Ham WS, Choi YD, Lee JY. Kwon JK, et al. BMC Urol. 2015 Jun 24;15:55. doi: 10.1186/s12894-015-0050-5. BMC Urol. 2015. PMID: 26104313 Free PMC article.
Alfuzosin (MD;-5.71, 95 % CI;-11.32--0.52) and tamsulosin (MD;-7.77, 95 % CI;-13.68--2.14) showed lower scores for BPS compared with placebo; however, the MD between alfuzosin and tamsulosin was not significant (MD; 2.12, 95 % CI;-4.62-8.72). ...Tamsulosin might be …
Alfuzosin (MD;-5.71, 95 % CI;-11.32--0.52) and tamsulosin (MD;-7.77, 95 % CI;-13.68--2.14) showed lower scores for BPS compared with …
Effects of Alfuzosin, an alpha(1)-Adrenergic Antagonist, on Anal Pressures and Bowel Habits in Women With and Without Defecatory Disorders.
Chakraborty S, Feuerhak K, Muthyala A, Harmsen WS, Bailey KR, Bharucha AE. Chakraborty S, et al. Clin Gastroenterol Hepatol. 2019 May;17(6):1138-1147.e3. doi: 10.1016/j.cgh.2018.08.036. Epub 2018 Aug 18. Clin Gastroenterol Hepatol. 2019. PMID: 30130627 Free PMC article. Clinical Trial.
We performed a randomized, placebo-controlled study of the effects of alfuzosin, an alpha1-adrenergic receptor antagonist, on anal pressures alone in healthy women and also on bowel symptoms in women with DD. ...However, alfuzosin did not significantly increase the …
We performed a randomized, placebo-controlled study of the effects of alfuzosin, an alpha1-adrenergic receptor antagonist, on anal pr …
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Jardin A, et al. Lancet. 1991 Jun 15;337(8755):1457-61. doi: 10.1016/0140-6736(91)93140-5. Lancet. 1991. PMID: 1710750 Clinical Trial.
To assess the long-term efficacy and safety of alfuzosin, a selective alpha 1-adrenergic antagonist, 518 symptomatic patients with benign prostatic hypertrophy (BPH) were randomised to received either alfuzosin (daily dose 7.5-10 mg) or placebo for 6 months. Obstruc …
To assess the long-term efficacy and safety of alfuzosin, a selective alpha 1-adrenergic antagonist, 518 symptomatic patients with be …
Effects of psychosensory stimulation on anal pressures: Effects of alfuzosin.
Muthyala A, Feuerhak KJ, Harmsen WS, Chakraborty S, Bailey KR, Bharucha AE. Muthyala A, et al. Neurogastroenterol Motil. 2019 Jul;31(7):e13618. doi: 10.1111/nmo.13618. Epub 2019 Apr 29. Neurogastroenterol Motil. 2019. PMID: 31032543 Free PMC article. Clinical Trial.
After relaxation, anal pressure declined (P = 0.0004) by 3 4 mm Hg in DD patients but not in controls. Alfuzosin reduced (P = 0.0001) anal resting pressure (by 31 19 mm Hg) vs placebo (16 18 mm Hg). ...Alfuzosin reduced anal resting pressure but did not block the St …
After relaxation, anal pressure declined (P = 0.0004) by 3 4 mm Hg in DD patients but not in controls. Alfuzosin reduced (P = 0.0001) …
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
Mehik A, Alas P, Nickel JC, Sarpola A, Helström PJ. Mehik A, et al. Urology. 2003 Sep;62(3):425-9. doi: 10.1016/s0090-4295(03)00466-7. Urology. 2003. PMID: 12946740 Clinical Trial.
The data from 66 patients were available for evaluation (17 in the alfuzosin, 20 in the placebo, and 29 in the control/standard group). At the end of 6 months of active therapy, the alfuzosin group had had a statistically significant decrease in total NIH-CPSI score …
The data from 66 patients were available for evaluation (17 in the alfuzosin, 20 in the placebo, and 29 in the control/standard group …
Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
Mondaini N, Giubilei G, Ungar A, Gontero P, Cai T, Gavazzi A, Bartoletti R, Geppetti P, Carini M. Mondaini N, et al. Eur Urol. 2006 Dec;50(6):1292-6; discussion 1297-8. doi: 10.1016/j.eururo.2006.06.016. Epub 2006 Jun 28. Eur Urol. 2006. PMID: 16837126 Clinical Trial.
OBJECTIVES: Alfuzosin 10mg is a uroselective alpha(1)-adrenoceptor antagonist used to treat lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ...No significant difference in either SBP, DBP, or HR was observed between the placebo and alfuzosin …
OBJECTIVES: Alfuzosin 10mg is a uroselective alpha(1)-adrenoceptor antagonist used to treat lower urinary tract symptoms suggestive o …
Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study.
Pedro RN, Hinck B, Hendlin K, Feia K, Canales BK, Monga M. Pedro RN, et al. J Urol. 2008 Jun;179(6):2244-7; discussion 2247. doi: 10.1016/j.juro.2008.01.141. Epub 2008 Apr 18. J Urol. 2008. PMID: 18423747 Clinical Trial.
PURPOSE: We evaluated the efficacy of alfuzosin as medical expulsive therapy for distal ureteral stone passage. MATERIALS AND METHODS: A total of 76 patients with a distal ureteral calculus provided consent for the study. ...RESULTS: The overall spontaneous stone passage r …
PURPOSE: We evaluated the efficacy of alfuzosin as medical expulsive therapy for distal ureteral stone passage. MATERIALS AND METHODS …
Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study.
Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Beddingfield R, et al. J Urol. 2009 Jan;181(1):170-6. doi: 10.1016/j.juro.2008.09.026. Epub 2008 Nov 14. J Urol. 2009. PMID: 19013590 Clinical Trial.
Regarding stent type, procedure complications and baseline questionnaire results there were no significant differences between the placebo and alfuzosin arms. When comparing post-procedure questionnaire results, patients in the alfuzosin arm reported less overall pa …
Regarding stent type, procedure complications and baseline questionnaire results there were no significant differences between the placebo a …
119 results